FDA Expands AbbVie’s Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

All NewsJune 11, 2025

FDA approves AbbVie’s Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent